Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

'Very-low-risk' bladder tumours - a new entity?

Ofer N Gofrit1, Dov Pode1, Galina Pizov2

  • 1Department of Urology, Hadassah Hebrew University Hospital, Jerusalem, Israel.

BJU International
|December 24, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ureteral obstruction caused by migration of a renal embolization coil 25 years after blunt renal trauma.

Urology case reports·2026
Same author

The Third Endourological Society Census Report.

Journal of endourology·2026
Same author

Endocannabinoid responses to relief of obstruction in acute injured kidney: a prospective observational study.

Therapeutic advances in urology·2026
Same author

Targeting Bladder Cancer with Inactivated Uropathogenic <i>E. coli</i>: A Novel Alternative to BCG Immunotherapy.

Cells·2026
Same author

Case Report: A potential novel treatment for drug-induced acute interstitial nephritis: Benralizumab.

Frontiers in immunology·2025
Same author

Partial nephrectomy Vs. Percutaneous thermal ablation of small renal masses.

Cancer treatment and research communications·2025

Low-risk bladder cancer patients are not a uniform group. Stratifying by tumor size can identify a "very-low-risk" subgroup with fewer recurrences, suggesting tailored follow-up protocols.

Area of Science:

  • Urology
  • Oncology
  • Cancer Research

Background:

  • The 'low-risk' bladder cancer group is often treated with standardized follow-up protocols.
  • Homogeneity within this group is questionable, potentially leading to suboptimal surveillance strategies.

Purpose of the Study:

  • To evaluate the heterogeneity of the 'low-risk' bladder cancer patient cohort.
  • To determine if tumor size can be used to optimize bladder cancer follow-up protocols.

Main Methods:

  • Retrospective analysis of 211 patients with low-risk bladder cancer treated between June 1998 and December 2008.
  • Standard follow-up included cystoscopy and ultrasonography over a median of 10 years.

Main Results:

  • Tumor recurrence occurred in 30.7% of patients, with 1.4% experiencing stage progression.
Keywords:
#BladderCancer#blcsmfollow-uplow-grade bladder cancerprognosisvery-low-grade bladder cancer

Related Experiment Videos

  • Patients with tumors ≤1 cm (40%) were younger and had significantly higher 5-year recurrence-free survival (92% vs. 70%).
  • Recurrences in smaller tumors (≤1 cm) were more likely to occur beyond 5 years (56.3%) compared to larger tumors (24.5%).

    • Conclusions:

    • Low-risk bladder cancer patients represent an inhomogeneous group that can be stratified by tumor size.
    • Patients with tumors ≤1 cm may constitute a 'very-low-risk' subgroup.
    • Tailored, potentially prolonged non-invasive surveillance strategies may be appropriate for this very-low-risk group.